Samsung Biologics CEO John Rim Secures Third Term, Vows to Accelerate 'Three-Pillar Expansion'

Samsung Biologics CEO John Rim, reappointed for a third term, pledges to accelerate expansion in production capacity, portfolio diversification, and global presence despite challenging market conditions, while advancing U.S. plant acquisition and domestic bio campus construction.